

## **DR. ROBERT BROOKINS NAMED ALEXIUM INTERIM CEO** Replaces Dirk Van Hyning, Who Resigned for Personal Reasons

### **Highlights:**

- Former Alexium CEO, Dirk Van Hyning, resigned on 31 May for personal reasons.
- Alexium's Board of Directors has appointed Alexium's Executive Vice President of Research and Development, Dr. Robert Brookins, as Interim CEO.
- Dr. Brookins has been with Alexium since 2010, has served Alexium in a variety of operational roles, and is the driver behind the development of the company's flame retardant technologies and Alexicool phase change material product line.
- Dr. Brookins has shown himself to be a commercially focused entrepreneur, working across the entire business with end customers, logistics, supply chain management, and product development.

**Perth, Australia, and Greer, South Carolina- 31 May 2018-** Alexium International Group Limited ("Alexium," "the Company," ASX: AJX, NASDAQ Designation: AXXIY) announces that Dr. Dirk Van Hyning has resigned from his position as Chief Executive Officer of the Company with effect from 31 May 2018, for personal reasons.

The Board has appointed as Interim CEO, Dr. Robert (Bob) Brookins who is currently Alexium's Executive Vice President of Research and Development and who has held operational roles with the company since 2010. As well as having been a major force in the development of the flame retardant technologies, Dr. Brookins has been the driver behind the evolution of Alexium's bedding market technologies and in particular the phase change material (PCM) product line Alexicool®.

In this respect, Dr. Brookins has shown himself to be a commercially focused entrepreneur.

He has been working across the entire business and in particular has been:

- orchestrating product development with end customers;
- working closely with sales and marketing;
- involved in all aspects of pricing, logistics and supply chain management; and
- developing metrics to demonstrate the superior performance of Alexium's products.

As such, over the past eight years, Dr. Brookins has developed from the research product developer to the innovator and joint market lead, and he has been instrumental in running the fast developing PCM part of the business from inception, development, and all the way to sales.

Dr. Brookins' team of product development and research scientists has been instrumental to this effort. This team has been integral to Alexium's growth and has facilitated Alexium's business model of providing innovative products to address critical gaps in the flame retardant and PCM markets. Their support has enabled Dr. Brookins to take on expanded operational roles and drive a holistic vision for Alexium growth.

**-CONTINUED-**

**-CONTINUED-**

Alexium Board Chair Susan Thomas said, “We are grateful to Dirk for his five years of service to Alexium and wish him all the best going forward. I am delighted that Bob Brookins has agreed to serve as Interim CEO. Dr. Brookins has been with the Company since its inception. He is a very familiar face to our customers and partners, as well as the investment community. He has been instrumental in the development of Alexium’s market leading, proprietary technologies and shown that he has an ability to work closely with product development and marketing to bring innovative products to market.”

Dr. Brookins said, “Alexium has reached an exciting stage where the performance of our products is gaining wide market awareness which positions the Company to gain greater penetration into current markets and expansion into new. Coordination of Alexium resources to accomplish this is my focus, and I look forward to driving this effort.”

See following page for Appendix 3Z (Final Director’s Interest Notice) for Dr. Van Hying.

**About Alexium International Group Limited**

Alexium International Group Limited (ASX: AJX, Nasdaq Designation: AXXIY) holds proprietary patent applications for novel technologies developed to provide flame retardancy for a wide range of materials. These environmentally friendly flame retardants have applications for several industries and can be customized. Further, Alexium has developed products for a range of other applications including phase-change materials, water repellents, antimicrobials, and combinations thereof. Alexium also holds patents for a process developed initially by the U.S. Department of Defense, which allows for the surface modification and attachment of nanoparticles or multiple chemical functional groups to surfaces or substrates to provide functions such as fire retardancy, water proofing, oil proofing, and antimicrobial treatments. Applications under development include but are not limited to textiles, packaging, electronics, and building materials. Alexium’s chemical treatments are currently marketed as Alexicool® and Alexiflam®. For additional information about Alexium, please visit [www.alexiuminternational.com](http://www.alexiuminternational.com).

**-END-**

**U.S. Contacts**

Bob Brookins, Interim CEO  
bbrookins@alexiuminternational.com

Mark Wise, VP Investor Relations  
mwise@alexiuminternational.com  
1.864.603.1211

**U.S. Corporate Office**

350 W. Phillips Rd.  
Greer, SC 29650 USA  
US: 1.864.254.9923

**Listing Information**

ABN: 91 064 820 408  
ASX: AJX  
Nasdaq Designation: AXXIY

# Appendix 3Z

## Final Director's Interest Notice

*Information or documents not available now must be given to ASX as soon as available. Information and documents given to ASX become ASX's property and may be made public.*

Introduced 30/9/2001.

<b>Name of entity</b>	<b>ALEXIUM INTERNATIONAL GROUP LIMITED</b>
<b>ABN</b>	<b>91 064 820 408</b>

We (the entity) give ASX the following information under listing rule 3.19A.3 and as agent for the director for the purposes of section 205G of the Corporations Act.

<b>Name of director</b>	Dirk Van Hying
<b>Date of last notice</b>	29/05/18
<b>Date that director ceased to be director</b>	31 May 2018

### Part 1 – Director's relevant interests in securities of which the director is the registered holder

*In the case of a trust, this includes interests in the trust made available by the responsible entity of the trust*

Note: In the case of a company, interests which come within paragraph (i) of the definition of "notifiable interest of a director" should be disclosed in this part.

<b>Number &amp; class of securities</b>
804,286 Ordinary Fully Paid Shares

+ See chapter 19 for defined terms.

## Appendix 3Z

### Final Director's Interest Notice

---

#### Part 2 – Director's relevant interests in securities of which the director is not the registered holder

Note: In the case of a company, interests which come within paragraph (ii) of the definition of "notifiable interest of a director" should be disclosed in this part.

*In the case of a trust, this includes interests in the trust made available by the responsible entity of the trust*

<b>Name of holder &amp; nature of interest</b> Note: Provide details of the circumstances giving rise to the relevant interest	<b>Number &amp; class of securities</b>
N/A	

#### Part 3 – Director's interests in contracts

<b>Detail of contract</b>	N/A
<b>Nature of interest</b>	N/A
<b>Name of registered holder (if issued securities)</b>	N/A
<b>No. and class of securities to which interest relates</b>	N/A

---

+ See chapter 19 for defined terms.